Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

383
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
383
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accurate imaging diagnosis of small pancreatic carcinoma/high-grade pancreatic intraepithelial neoplasia using combined indirect imaging findings.

Digestion·2026
Same author

Protective effects of PRELP protein in a mouse model of pulmonary fibrosis.

Respiratory research·2026
Same author

Isolated Subcarinal Lymph Node Recurrence 24 Years After Treatment for Primary Tracheal Adenoid Cystic Carcinoma.

Respirology case reports·2026
Same author

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy.

Cancer science·2026
Same author

Precision medicine in the first-line treatment of <i>EGFR</i>-mutated non-small cell lung cancer: moving beyond "one-size-fits-all".

Translational lung cancer research·2026
Same author

Clinicogenomic Landscape of <i>MTAP</i>-Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent <i>CDKN2A</i> Alterations and Driver Mutations.

JCO precision oncology·2026

Related Experiment Video

Updated: Jul 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case

Koki Fujii1, Kensuke Fukuda1, Masanori Kawakami1

  • 1Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo, Japan.

Case Reports in Oncology
|October 30, 2023
PubMed
Summary
This summary is machine-generated.

This case study shows that cancer immunity may persist during long-term immune checkpoint inhibitor therapy. Pembrolizumab treatment in lung adenocarcinoma patients may allow for further immune activation, even after COVID-19 vaccination.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Lung adenocarcinoma is a significant cause of cancer-related mortality.
Keywords:
Immune checkpoint inhibitorsImmunotherapyLung neoplasmsVaccination

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.1K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K

Related Experiment Videos

Last Updated: Jul 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.1K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K
  • Immune checkpoint inhibitors (ICIs) like pembrolizumab have revolutionized cancer treatment.
  • The interaction between cancer immunity, ICIs, and vaccination requires further investigation.